BioAsia to begin in Hyderabad from today

BioAsia, the annual flagship event of the Government of Telangana, will deliberate on a range of issues plaguing the Indian Pharma sector, including the revenue loss impacting Indian companies and decreasing market capitalisation due to increasing regulatory concerns from the United States and European markets. Increasing number of import alerts and warning letters is making it difficult for Indian companies doing business in the West regions.

The event scheduled for February 22-24 is expected to witness participation of 1,600 delegates from over 52 countries with 100 high profile speakers and 500 corporates.

The idea of the event is preparing the industry to face these challenges and embrace the change. We have five core focus areas this year-innovation, cancer diagnostics, supply chain and



logistics, digital health and regulations. This is the first time the USFDA is partnering with BioAsia to hold a dedicated session on regulations.”

The State government is making all its efforts to make this event big as it readies to host the 15the edition of BioAsia this year. Ireland is the partner country. And Malaysia, South Korea, Netherlands, Belgium and South Africa are sending large delegations to the event. Governments and industry are taking part in these delegations. The global response has been phenomenal, he informed.

The inaugural of the programme is scheduled at 6pm on Thursday. Biocon’s founder Kiran Mazumdar and other senior industry leaders from the bio-pharmaceuticals are going to take part in the CEO Conclave as well as key sector sessions.